Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have posted below a list of anti-virals currently in trial. This is from a link from the Merck article. https://www.evaluate.com/vantage/articles/news/trial-results/molnupiravirs-big-day-draws-near
Best to all
Spinnaker
I think SNG still looks very solid subject to positive trials and not too much delay on the international P3. I would expect that we should have information from the P2 home trial before Activ 2 but this may not be adequate to change the status quo significantly. Activ 2 and submission for EUA /roll-on to P3 will be the more significant early SP catalyst IMO
Antivirals in development for Covid-19
Project Company Setting Note
Veklury (IV) Gilead FDA-approved in Covid-19 patients requiring hospitalisation Repurposed Ebola research project
Molnupiravir (oral) Merck & Co/Ridgeback Ph2/3 trials in hospitalised (NCT04575584) and non-hospitalised (NCT04575597) pts ongoing Repurposed flu antiviral
AT-527 (oral) Roche/Atea Ph2 trial in hospitalised patients (NCT04396106) ongoing; non-hospitalised trial due to start (NCT04709835) Repurposed hep C antiviral
PF-07304814 (IV) Pfizer Ph1b ongoing in hospitalised patients (NCT04535167, excludes severely ill or with certain pre-existing conditions) Repurposed SARS research project
MP0420 (ensovibep; IV) Novartis/Molecular Partners Ph1 trial in UK ongoing in healthy volunteers Designed for SARS-Cov-2
MP0423 Novartis/Molecular Partners Preclinical Designed for SARS-Cov-2; could be better against variants than MP0420 due to different targeting mechanisms
Source: EvaluatePharma & clinicaltrials.gov.
Nebulised cannabis is the holy grail.
Worthington. Wtf. Your saying cannabis can be used as a treatment and a competitor of Sng001 and Sng016 treatments. Ffs, your having a laugh.
...if interferon response interests you, GWPharma and other mary j biotechs may be worth investigating https://www.forbes.com/sites/emilyearlenbaugh/2020/07/06/cannabis-may-reduce-deadly-covid-19-lung-inflammation-researchers-explain-why/
The science of the Interferon response is fundamental and is why I bought SNG.
I still believe it "should" work in other conditions. I guess I'd read to many "its nailed on, dead cert etc" posts before I got here. Apologies Schrow.
Apologies for double post
Spinn
Thanks for that post and link Johnny.
I see this was a tiny trial of critically ill patients based on licence on compassionate use grounds. The tablets performed better than hydroxchloroquine. I saw reference to another larger trial and will try and check that out.
Spinnaker
Thanks for that post and link Johnny.
I see this was a tiny trial of critically ill patients based on licence on compassionate use grounds. The tablets performed better than hydroxchloroquine. I saw reference to another larger trial and will try and check that out.
Spinnaker
"the science is still basically irrefutable, the opportunities still massive"
Basic physiological science is one thing - performance in a randomised clinical trial is something else. If there was no risk the SP would have already exploded. I've been here for quite some time and happy to stay but think recognising the risk reward balance in a changing market place is healthy - no need for over stating the case unless warm feelings serve some sort of purpose.
I'm half expecting CityTTrader to pop on here and tell us that his sources got this mixed up but a TR1 Friday from a Sri Lankan buyer is incoming.
@Org, glad it's not just me who has the Tuesday morning blues.
Not feeling confident about hearing any news this week and the slide of the SP has put some doubts in my mind again. Need to switch back on, remain positive and wait for the next news to drop.
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext
The above is a link to an Ebiome/Lancet paper dated 3 March 2021 on the only other non I/V treatment currently in Activ 2 with SNG001. Janet Wood**** and others have postulated that the Holy Grail for Cov19 early treatment would be a tablet. This is a tablet , two doses per day for five days postulated. It is far too scientific for me to postulate an opinion or explanation but others may have a view. I should note that this paper appears to bear no relation to Sagent who I believe are the sponsors for the drug in Activ2 trials.
I don't know if there have been any human trials yet but this publication appears to be only related to ex-vivo studies so presumably does not have the evidence of efficacy that SNG001 has to date.
This may already have been posted here in which case, my apologies. Also there may be other in-vivo studies which I haven't seen.
I would expect that inhaled treatment would be preferred to I/V or Intramuscular injection for pre hospital treatment and there must be concerns that mAbs are sensitive to variation of the virus. At my basic level of understanding therefore I would think that SNG would be readily taken to P3 and EUA if efficacy is shown. Also and importantly it should be a popular method of treatment including pre-hospitalisation.
Spinnaker